# SPTX (Seaport Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Seaport Therapeutics, Inc. reported $417.6M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SPTX
- Markdown: https://convexityos.com/fundamentals/SPTX.md
- SEC CIK: 0002042347
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:29 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002042347&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $290.4M | Total debt: $4.69M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $23.89M | $24.62M | $21.43M | $20.45M | $13.41M | $10.53M |
| Total Operating Expenses | $30.34M | $65.81M | $27.54M | $25.44M | $18.47M | $16.18M |
| **Operating Income** | -$30.34M | -$65.81M | -$27.54M | -$25.44M | -$18.47M | -$16.18M |
| **EBITDA** | -$30.32M | -$65.78M | -$27.52M | -$25.39M | -$18.43M | -$16.15M |
| Income Before Tax | -$26.27M | -$62.35M | -$24.89M | -$22.45M | -$14.94M | -$13.09M |
| Income Tax Expense | $127K | $251K | $519K | $95K | $134K | $31K |
| **Net Income** | -$26.39M | -$62.60M | -$25.41M | -$22.54M | -$15.08M | -$13.12M |
| Basic EPS | -$0.49 | -$1.78 | -$32.47 | -$9.43 | -$6.40 | -$17.75 |
| **Diluted EPS** | -$0.49 | -$1.78 | -$32.47 | -$9.43 | -$6.40 | -$17.75 |
| Basic Shares Outstanding | 53.5M | 35.2M | 782.2K | 2.4M | 2.4M | 739.9K |
| Diluted Shares Outstanding | 53.5M | 35.2M | 782.2K | 2.4M | 2.4M | 739.9K |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $61.55M | $64.22M | $52.91M | $46.04M |
| Short-Term Investments | $228.9M | $209.1M | $129.7M | $169.9M |
| **Cash & Short-Term Investments** | $290.4M | $273.3M | $182.6M | $216.0M |
| **Total Current Assets** | $299.1M | $282.2M | $188.3M | $223.2M |
| Property, Plant & Equipment, Net | $333K | $360K | $386K | $412K |
| Long-Term Investments | $113.4M | $154.0M | $30.04M | $17.67M |
| Other Non-Current Assets | $454K | $454K | $3.84M | $2.88M |
| **Total Non-Current Assets** | $118.6M | $159.5M | $39.33M | $25.78M |
| **Total Assets** | $417.6M | $441.7M | $227.7M | $249.0M |
| Accounts Payable | $5.81M | $5.71M | $4.79M | $2.01M |
| Other Current Liabilities | $0 | $0 | $11K | $7.0K |
| **Total Current Liabilities** | $17.11M | $15.67M | $14.22M | $12.78M |
| **Total Non-Current Liabilities** | $3.06M | $3.40M | $3.74M | $3.44M |
| **Total Liabilities** | $20.17M | $19.08M | $17.97M | $16.23M |
| **Total Debt (incl. Leases)** | $4.69M | $5.02M | $5.34M | $5.08M |
| Common Stock | $5.0K | $5.0K | $1.0K | $1.0K |
| Retained Earnings | -$228.5M | -$202.1M | -$139.5M | -$114.1M |
| Accumulated Other Comp. Income | -$1.68M | -$475K | $64K | $301K |
| **Total Stockholders' Equity** | $397.5M | $422.6M | -$115.6M | -$92.55M |
| Total Equity | $397.5M | $422.6M | -$115.6M | -$92.55M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$26.39M | -$62.60M | -$25.41M | -$22.54M | -$15.08M | -$13.12M |
| Depreciation & Amortization | $27K | $26K | $26K | $54K | $41K | $36K |
| Stock-Based Compensation | $2.45M | $36.86M | $2.57M | $1.78M | $1.76M | $1.62M |
| Change in Payables | $112K | $910K | $2.78M | $2.40M | -$601K | -$2.00M |
| **Operating Cash Flow** | -$22.68M | -$26.14M | -$20.17M | -$15.77M | -$15.32M | -$20.20M |
| Capital Expenditure | $0 | $0 | $0 | -$8.0K | -$269K | -$54K |
| **Free Cash Flow** | -$22.68M | -$26.14M | -$20.17M | -$15.77M | -$15.59M | -$20.26M |
| Purchases of Investments | -$24.89M | -$253.5M | -$47.15M | -$49.90M | -$78.67M | -$225.5M |
| **Investing Cash Flow** | $20.11M | -$203.5M | $27.85M | $15.09M | -$1.44M | -$225.6M |
| **Financing Cash Flow** | -$97K | $240.9M | -$783K | $1.0K | $0 | $0 |
| **Net Change in Cash** | -$2.67M | $11.31M | $6.87M | -$641K | -$16.77M | -$245.8M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 17.48x | 18.00x | 13.24x | -- | -- | -- |
| Quick Ratio | 16.98x | 17.44x | 12.84x | -- | -- | -- |
| Debt to Equity | 0.01x | 0.01x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
